Editorial

• Volume 8 Number 11/12 November/December 2007

Conference reports

• 11th European AIDS conference (EACS), October 24-27 2007, Madrid

• New European guidelines launched

• Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)

• Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)

• Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

• Drug interaction studies presented at EACS

Antiretrovirals

• Half-dose Kaletra tablet approved for paediatric use in the US

Guidelines

• US adult treatment guidelines updated

• US updates guidelines on use of ARVs during pregnancy

Side effects

• Case report of efavirenz-associated nephrolithiasis

• Yellow card reporting scheme for doctors and patients in the UK

PMTCT and maternal health

• Perinatal transmission of HIV in England 2002-2005

• Risk factors for in utero or intrapartum mother-to-child transmission in Thailand

TB coinfection

• HIV and TB co-infection and treatment charges in the UK

PK and drug interactions

• New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives

• Acid reducing agents and protese inhibitors

• Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment

• T-20 increases tipranavir levels but not hepatotoxicity

• The effect of lopinavir/r on the renal clearance of tenofovir

Vaccines and microbicides

• Merck HIV vaccine trial is unblinded

Other news

• IAS statement on US policy for HIV-positive visitors

On the web

• PLoS Medicine articles

• HIV/TB co-infection: meeting the challenge

PDFs

• Volume 8 Number 11/12 November/December 2007 PDF